Open AccessAntenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial
Author(s) -
Jim Aizire,
Kristina M Brooks,
Mark Mirochnick,
Patricia M. Flynn,
Kevin Butler,
Jennifer J. Kiser,
George K. Siberry,
Terry Fenton,
Mae Cababasay,
Mary Glenn Fowler,
Promise study team
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002247
Subject(s) - emtricitabine , medicine , interquartile range , lopinavir , pregnancy , odds ratio , adverse effect , ritonavir , gestational age , gestation , confidence interval , obstetrics , viral load , human immunodeficiency virus (hiv) , immunology , biology , covid-19 , disease , antiretroviral therapy , infectious disease (medical specialty) , genetics
In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, tenofovir disoproxil fumarate (TDF) use was associated with moderate or severe adverse pregnancy/neonatal outcomes. This study characterized tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) concentrations in dried blood spots (DBS) and assessed association between severe adverse pregnancy/neonatal outcomes and TFV-DP concentration.